The introduction of five upcoming registrational readouts for 2026 is a new forward-looking highlight. Product net sales and operating profit both increased meaningfully quarter-over-quarter, as did ...

The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...

Coffee is a staple for many, but according to nutritionist Lovneet Batra, there are certain situations when women should ...

Merck & Eisai announce Welireg plus Lenvima meets primary endpoint of PFS in certain previously treated patients with advanced RCC: Rahway, New Jersey Wednesday, October 29, 2025, ...

Iron deficiency is common in female athletes and can drain energy and performance. Learn how optimizing iron intake supports ...

In combination with pembrolizumab, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). In combination with everolimus, for the treatment of adult patients with ...

Bristol Myers Squibb today announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic ...

On August 7, 2025, the Food and Drug Administration announced that it would be demanding the elimination of natural thyroid treatment, otherwise known as desiccated thyroid extract (DTE) or natural ...

The FDA approved elinzanetant (Lynkuet), a new type of nonhormonal drug to treat disruptive menopausal hot flashes, Bayer ...

Investing.com -- Argenx (EBR: ARGX) shares climbed more than 2% on Thursday after the Belgian biopharmaceutical company reported third-quarter results that exceeded forecasts, led by stronger product ...

Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With ...

Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...